



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Marc ALIZON et al.:) Group Art Unit: 1637
)
Application No.: 08/308,219) Examiner: Jeffrey Norman Fredman
)
Filed: September 19, 1994) Confirmation No.: 4832
)
For: DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) (as amended)

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Applicants submit the following paper. The items checked below are appropriate:

- ☒ An Amendment and Response (8 pages) is enclosed. The claims are calculated as follows:

	Claims Remaining After Amendment		Highest Number Previously Paid	Present Extra	Rate	Additional Fee
Total	12	-	20	0	x \$ 18	\$ -0-
Indep.	2	-	3	0	x \$ 84	-0-
<input type="checkbox"/> First Presentation of Multiple Dep. Claim(s)					+\$280	-0-
Subtotal						\$ -0-
Reduction by 1/2 if small entity						- -0-
TOTAL						\$ -0-

- ☒ No additional claims fee is due.


Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: May 18, 2004

By: _____


Salvatore J. Arrigo
Registration No. 46,063
Telephone: 202-408-4160
Facsimile: 202-408-4400
E-mail: arrigos@finnegan.com

FW



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Marc ALIZON et al.) Group Art Unit: 1637 ✓
)
Application No.: 08/308,219) Examiner: Jeffrey Norman Fredman
)
Filed: September 19, 1994) Confirmation No.: 4832
)
For: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY
VIRUS TYPE 1 (HIV-1) (as amended)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT AND RESPONSE

In response to the Office Action dated April 13, 2004, applicants submit the following amendments and remarks. Please amend this application as follows.

Amendments to the Claims are reflected in the listing of claims in this paper.

Remarks begin on page 6 of this paper.